Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan flat-sum changes may boost generic uptake further

This article was originally published in Scrip

Executive Summary

Japan's central social insurance medical council (Chuikyo) is debating a possible change to the diagnosis procedure combination (DPC) reimbursement system to encourage the use of generic drugs. But at a recent council hearing, no consensus was reached on a ministry of health, labour and welfare proposal to better reward generic use under the DPC evaluation system. The DPC programme involves flat-sum reimbursement for all acute inpatient care costs, including drugs, and is being implemented at an increasing number of hospitals in Japan. It is itself expected to drive generic uptake, as hospitals look to contain costs within the fixed figure (Scrip Online, October 7th, 2008).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts